{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T17:33:41Z","timestamp":1783791221115,"version":"3.55.0"},"reference-count":83,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Vaccinations provided the most effective tool to fight the SARS-CoV-2 pandemic. It is now well established that COVID-19 vaccines are safe for the general population; however, some cases of rare adverse events following immunization have been described, including CNS Inflammatory Demyelinating Events (CIDEs). Although observational studies are showing that these events are rare and vaccines' benefits highly outweigh the risks, collecting and characterizing post-COVID-19 vaccine CIDEs might be relevant to single out potential risk factors and suggest possible underlying mechanisms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Here we describe six CIDEs, including two acute transverse myelitis (ATM), three multiple sclerosis (MS), and one neuromyelitis optica spectrum disorder (NMOSD), occurring between 8 and 35 days from a COVID-19 vaccine. Moreover, we performed a systematic literature search of post-COVID-19 vaccines CIDEs, including ATM, ADEM, MS, and NMOSD\/MOGAD, published worldwide between December 2020 and December 2021, during 1 year of the vaccination campaign. Clinical\/MRI and CSF\/serum characteristics were extracted from reviewed studies and pooled-analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty-nine studies were included in the systematic review, reporting a total amount of 85 CIDEs. Considering our additional six cases, 91 CIDEs were summarized, including 24 ATM, 11 ADEM, 47 MS, and nine NMOSD\/MOGAD. Overall, CIDEs occurred after both mRNA (<jats:italic>n<\/jats:italic> = 46), adenoviral-vectored (<jats:italic>n<\/jats:italic> = 37), and inactivated vaccines (<jats:italic>n<\/jats:italic> = 8). Adenoviral-vectored vaccines accounted for the majority of ADEM (55%) and NMOSD\/MOGAD (56%), while mRNA vaccines were more frequent in MS new diagnoses (87%) and relapses (56%). Age was heterogeneous (19\u201388) and the female sex was prevalent. Time from vaccine to symptoms onset was notably variable: ADEM and NMOSD\/MOGAD had a longer median time of onset (12.5 and 10 days) compared to ATM and MS (6 and 7 days) and further timing differences were observed between events following different vaccine types, with ATM and MS after mRNA-vaccines occurring earlier than those following adenoviral-vectored ones.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Both the prevalence of vaccine types for certain CIDEs and the heterogeneity in time of onset suggest that different mechanisms\u2014with distinct dynamic\/kinetic\u2014might underly these events. While epidemiological studies have assessed the safety of COVID-19 vaccines, descriptions and pooled analyses of sporadic cases may still be valuable to gain insights into CIDE's pathophysiology.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.1018785","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T16:22:45Z","timestamp":1669911765000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["CNS inflammatory demyelinating events after COVID-19 vaccines: A case series and systematic review"],"prefix":"10.3389","volume":"13","author":[{"given":"Virginia","family":"Rinaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Bellucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Buscarinu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Reni\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Nasello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Zancan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Nistri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Salerno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Salvetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Ristori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26COV2S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 vaccines against the B16172 (delta) variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/S0140-6736(21)00677-2","article-title":"Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study","volume":"397","author":"Vasileiou","year":"2021","journal-title":"Lancet."},{"key":"B7","unstructured":"Trackvaccines.org"},{"key":"B8","unstructured":"Who.int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"577765","DOI":"10.1016\/j.jneuroim.2021.577765","article-title":"A systematic review of cases of CNS demyelination following COVID-19 vaccination","volume":"362","author":"Ismail","year":"2022","journal-title":"J Neuroimmunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","volume":"27","author":"Patone","year":"2021","journal-title":"Nat Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1177\/13524585211003476","article-title":"COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021","volume":"27","author":"Achiron","year":"2021","journal-title":"Mult Scler."},{"key":"B12","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1136\/jnnp-2021-327200","article-title":"mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis","volume":"93","author":"Di Filippo","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B13","doi-asserted-by":"publisher","first-page":"103424","DOI":"10.1016\/j.msard.2021.103424","article-title":"Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD","volume":"58","author":"Dinoto","year":"2022","journal-title":"Mult Scler Relat Disord."},{"key":"B14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1212\/WNL.59.4.499","article-title":"Proposed diagnostic criteria and nosology of acute transverse myelitis","volume":"59","year":"2002","journal-title":"Neurology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1212\/WNL.0000000000002825","article-title":"Acute disseminated encephalomyelitis: updates on an inflammatory CNS syndrome","volume":"87","author":"Pohl","year":"2016","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","article-title":"MOG encephalomyelitis: international recommendations on diagnosis and antibody testing","volume":"15","author":"Jarius","year":"2018","journal-title":"J Neuroinflammation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/qjmed\/hcab069","article-title":"COVID-19 vaccination-associated myelitis","volume":"114","author":"Malhotra","year":"2021","journal-title":"QJM."},{"key":"B20","doi-asserted-by":"publisher","first-page":"577606","DOI":"10.1016\/j.jneuroim.2021.577606","article-title":"A case of longitudinally extensive transverse myelitis following vaccination against Covid-19","volume":"358","author":"Pagenkopf","year":"2021","journal-title":"J Neuroimmunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"577686","DOI":"10.1016\/j.jneuroim.2021.577686","article-title":"Acute myelitis and ChAdOx1 nCoV-19 vaccine: casual or causal association?","volume":"359","author":"Vegezzi","year":"2021","journal-title":"J Neuroimmunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e535","DOI":"10.7861\/clinmed.2021-0470","article-title":"Lessons of the month 1: longitudinal extensive transverse myelitis following AstraZeneca COVID-19 vaccination","volume":"21","author":"Notghi","year":"2021","journal-title":"Clin Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3390\/medicina57101010","article-title":"Acute transverse myelitis after COVID-19 vaccination","volume":"57","author":"Hsiao","year":"2021","journal-title":"Medicina."},{"key":"B24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12883-021-02427-x","article-title":"Longitudinal extensive transverse myelitis following ChAdOx1 nCOV-19 vaccine: a case report","volume":"21","author":"Tan","year":"2021","journal-title":"BMC Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.clinimag.2021.08.021","article-title":"Neurological symptoms and neuroimaging alterations related with COVID-19 vaccine: cause or coincidence?","volume":"80","author":"Corr\u00eaa","year":"2021","journal-title":"Clin Imaging."},{"key":"B26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/cen3.12684","article-title":"Transverse myelitis and coronavirus disease 2019 vaccine: a temporal association","volume":"13","author":"Silva","year":"2022","journal-title":"Clin Exp Neuroimmunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"526","DOI":"10.30574\/wjarr.2021.12.2.0613","article-title":"Longitudinal extensive transverse myelitis with sixth nerve palsy post ChAdOx1 nCov-19 vaccine: a case report and literature review","volume":"12","author":"Kawtharani","year":"2021","journal-title":"World J Adv Res Rev"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e16624","DOI":"10.7759\/cureus.16624","article-title":"SARS-CoV-2 vaccination-induced transverse myelitis","volume":"13","author":"Tahir","year":"2021","journal-title":"Cureus."},{"key":"B29","doi-asserted-by":"publisher","first-page":"100019","DOI":"10.1016\/j.nerep.2021.100019","article-title":"Transverse myelitis 48 hours after the administration of an mRNA COVID 19 vaccine","volume":"1","author":"McLean","year":"2021","journal-title":"Neuroimmunol Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e20460","DOI":"10.7759\/cureus.20460","article-title":"Incomplete subacute transverse myelitis following vaccination with Pfizer-BioNTech COVID-19 mRNA vaccine: a case report","volume":"13","author":"Alabkal","year":"2021","journal-title":"Cureus."},{"key":"B31","doi-asserted-by":"publisher","first-page":"120102","DOI":"10.1016\/j.jns.2021.120102","article-title":"Acute transverse myelitis after BNT162b2 vaccination against COVID-19: report of a fatal case and review of the literature","volume":"434","author":"Nakano","year":"2022","journal-title":"J Neurol Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"739","DOI":"10.2169\/internalmedicine.8747-21","article-title":"Refractory longitudinally extensive transverse myelitis after severe acute respiratory syndrome Coronavirus 2 vaccination in a Japanese man","volume":"61","author":"Miyaue","year":"2022","journal-title":"Intern Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00415-021-10785-2","article-title":"Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature","volume":"269","author":"Khan","year":"2022","journal-title":"J Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.3390\/vaccines9091008","article-title":"Acute transverse myelitis following COVID-19 vaccination","volume":"9","author":"Gao","year":"2021","journal-title":"Vaccines."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e28423","DOI":"10.1097\/MD.0000000000028423","article-title":"Acute autoimmune transverse myelitis following COVID-19 vaccination: a case report: a case report","volume":"100","author":"Hirose","year":"2021","journal-title":"Medicine."},{"key":"B36","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3390\/neurolint13040061","article-title":"Spectrum of neuroimaging findings in post-COVID-19 vaccination: a case series and review of literature","volume":"13","author":"Sriwastava","year":"2021","journal-title":"Neurol Int."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e17961","DOI":"10.7759\/cureus.17961","article-title":"Neuromyelitis optica in a healthy female after severe acute respiratory syndrome Coronavirus 2 mRNA-1273 vaccine","volume":"13","author":"Fujikawa","year":"2021","journal-title":"Cureus."},{"key":"B38","doi-asserted-by":"publisher","first-page":"273","DOI":"10.18071\/isz.74.0273","article-title":"Acute transverse myelitis after inactivated COVID-19 vaccine","volume":"74","author":"Erdem","year":"2021","journal-title":"Ideggyogy Sz."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e21875","DOI":"10.7759\/cureus.21875","article-title":"Interstitial lung disease and transverse myelitis: a possible complication of COVID-19 vaccine","volume":"14","author":"Khan","year":"2022","journal-title":"Cureus."},{"key":"B40","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.radcr.2021.10.053","article-title":"Cervical longitudinally extensive myelitis after vaccination with inactivated virus-based COVID-19 vaccine","volume":"17","author":"Sepahvand","year":"2022","journal-title":"Radiol Case Rep."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1177\/13524585211040222","article-title":"ADEM after ChAdOx1 nCoV-19 vaccine: a case report","volume":"28","author":"Rinaldi","year":"2022","journal-title":"Mult Scler."},{"key":"B42","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s12024-021-00440-7","article-title":"Acute disseminated encephalomyelitis (ADEM) following recent Oxford\/AstraZeneca COVID-19 vaccination","volume":"18","author":"Permezel","year":"2022","journal-title":"Forensic Sci Med Pathol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"820049","DOI":"10.3389\/fneur.2021.820049","article-title":"Case series: acute hemorrhagic encephalomyelitis after SARS-CoV-2 vaccination","volume":"12","author":"Ancau","year":"2021","journal-title":"Front Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"006","DOI":"10.37871\/ijnd.id41","article-title":"Acute disseminated encephalomyelitis following sputnik V COVID-19 vaccine: a case report","volume":"5","author":"Shalilahmadi","year":"2021","journal-title":"Int J Neurol Dis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"100381","DOI":"10.1016\/j.ensci.2021.100381","article-title":"An 88-year-old woman with acute disseminated encephalomyelitis following messenger ribonucleic acid-based COVID-19 vaccination","volume":"25","author":"Shimizu","year":"2021","journal-title":"eNeurologicalSci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"106839","DOI":"10.1016\/j.clineuro.2021.106839","article-title":"Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination","volume":"208","author":"Vogrig","year":"2021","journal-title":"Clin Neurol Neurosurg."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1002\/acn3.51447","article-title":"Acute disseminated encephalomyelitis in a patient vaccinated against SARS-CoV-2","volume":"8","author":"Kania","year":"2021","journal-title":"Ann Clin Transl Neurol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s13760-021-01608-2","article-title":"Acute disseminated encephalomyelitis after severe acute respiratory syndrome coronavirus 2 vaccination: a case report","volume":"122","author":"Cao","year":"2022","journal-title":"Acta Neurol Belg."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s13760-021-01699-x","article-title":"Acute disseminated encephalomyelitis-like presentation after an inactivated coronavirus vaccine","volume":"121","author":"Ozgen Kenangil","year":"2021","journal-title":"Acta Neurol Belg."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00415-021-10780-7","article-title":"COVID-19 mRNA vaccination leading to CNS inflammation: a case series","volume":"269","author":"Khayat-Khoei","year":"2022","journal-title":"J Neurol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00415-021-10648-w","article-title":"First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine","volume":"269","author":"Havla","year":"2022","journal-title":"J Neurol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/vaccines9050435","article-title":"Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA\/DNA SARS-CoV-2 vaccination","volume":"9","author":"Watad","year":"2021","journal-title":"Vaccines."},{"key":"B53","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1080\/20009666.2021.1979745","article-title":"A rare presentation of undiagnosed multiple sclerosis after the COVID-19 vaccine","volume":"11","author":"Tagliaferri","year":"2021","journal-title":"J Community Hosp Intern Med Perspect."},{"key":"B54","doi-asserted-by":"publisher","first-page":"577755","DOI":"10.1016\/j.jneuroim.2021.577755","article-title":"Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine","volume":"361","author":"Fujimori","year":"2021","journal-title":"J Neuroimmunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"577785","DOI":"10.1016\/j.jneuroim.2021.577785","article-title":"New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure","volume":"362","author":"Toljan","year":"2022","journal-title":"J Neuroimmunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"765954","DOI":"10.3389\/fneur.2021.765954","article-title":"Case report: multiple sclerosis relapses after vaccination against SARS-CoV2: a series of clinical cases","volume":"12","author":"Nistri","year":"2021","journal-title":"Front Neurol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"721502","DOI":"10.3389\/fneur.2021.721502","article-title":"Severe multiple sclerosis relapse after COVID-19 vaccination: a case report","volume":"12","author":"Maniscalco","year":"2021","journal-title":"Front Neurol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"103321","DOI":"10.1016\/j.msard.2021.103321","article-title":"New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19","volume":"57","author":"Fragoso","year":"2022","journal-title":"Mult Scler Relat Disord."},{"key":"B59","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00415-021-10647-x","article-title":"Acute bilateral optic\/chiasm neuritis with longitudinal extensive transverse myelitis in longstanding stable multiple sclerosis following vector-based vaccination against the SARS-CoV-2","volume":"269","author":"Helmchen","year":"2022","journal-title":"J Neurol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"100006","DOI":"10.1016\/j.nerep.2021.100006","article-title":"COVID-19 vaccine (ChAdOx1 nCoV-19 Corona virus vaccine (Recombinant) \u2013 COVISHIELD related MS relapse","volume":"1","author":"Mathew","year":"2021","journal-title":"Neuroimmunol Rep."},{"key":"B61","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1080\/21645515.2021.1928463","article-title":"Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient","volume":"17","author":"Etemadifar","year":"2021","journal-title":"Hum Vaccin Immunother."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13760-021-01775-2","article-title":"Acute attack in a patient with multiple sclerosis 2 days after COVID vaccination: a case report","author":"Seyed Ahadi","year":"2021","journal-title":"Acta Neurol Belg"},{"key":"B63","doi-asserted-by":"publisher","first-page":"103414","DOI":"10.1016\/j.msard.2021.103414","article-title":"Newly diagnosed neuromyelitis optica spectrum disorders following vaccination: case report and systematic review","volume":"58","author":"Anamnart","year":"2022","journal-title":"Mult Scler Relat Disord."},{"key":"B64","doi-asserted-by":"publisher","first-page":"100016","DOI":"10.1016\/j.nerep.2021.100016","article-title":"Serum negative neuromyelitis optica spectrum disorder after vaxzevria vaccination: a case report","volume":"1","author":"Gorgone","year":"2021","journal-title":"Neuroimmunol Rep."},{"key":"B65","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1016\/j.radcr.2021.09.033","article-title":"Post COVID-19 vaccination neuromyelitis optica spectrum disorder: case report & MRI findings","volume":"16","author":"Badrawi","year":"2021","journal-title":"Radiol Case Rep."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1007\/s10072-021-05427-4","article-title":"Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19","volume":"42","author":"Chen","year":"2021","journal-title":"Neurol Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/13524585211057512","article-title":"MOG-antibody-associated longitudinal extensive myelitis after ChAdOx1 nCoV-19 vaccination","volume":"28","author":"Dams","year":"2022","journal-title":"Mult Scler."},{"key":"B68","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.autrev.2013.10.003","article-title":"The spectrum of post-vaccination inflammatory CNS demyelinating syndromes","volume":"13","author":"Karussis","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1177\/0961203309345730","article-title":"Transverse myelitis and vaccines: a multi-analysis","volume":"18","author":"Agmon-Levin","year":"2009","journal-title":"Lupus."},{"key":"B70","year":"2012"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e1167","DOI":"10.1212\/NXI.0000000000001167","article-title":"Pure relapsing short myelitis: part of the multiple sclerosis spectrum or new entity?","volume":"9","author":"Poullet","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B72","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S1474-4422(22)00086-2","article-title":"Epstein-Barr virus and multiple sclerosis: supporting causality","volume":"21","author":"Aloisi","year":"2022","journal-title":"Lancet Neurol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e77766","DOI":"10.1371\/journal.pone.0077766","article-title":"Acute disseminated encephalomyelitis onset: evaluation based on vaccine adverse events reporting systems","volume":"8","author":"Pellegrino","year":"2013","journal-title":"PLoS ONE."},{"key":"B74","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat Rev Immunol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain\u2013Barr\u00e9 syndrome: pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"Van den Berg","year":"2014","journal-title":"Nat Rev Neurol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41586-021-03744-4","article-title":"Antibody epitopes in vaccine-induced immune thrombotic thrombocytopaenia","volume":"596","author":"Huynh","year":"2021","journal-title":"Nature."},{"key":"B77","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/tpj.2015.21","article-title":"The role of Toll-like receptor 4 polymorphisms in vaccine immune response","volume":"16","author":"Pellegrino","year":"2016","journal-title":"Pharmacogenomics J."},{"key":"B78","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00415-021-10752-x","article-title":"Association of CNS demyelination and COVID-19 infection: an updated systematic review","volume":"269","author":"Ismail","year":"2022","journal-title":"J Neurol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"695","DOI":"10.3390\/neurolint13040066","article-title":"Clinical onset and multiple sclerosis replapses after SARS-CoV-2 infection","volume":"13","author":"Pignolo","year":"2021","journal-title":"Neurol Int."},{"key":"B80","doi-asserted-by":"publisher","first-page":"102947","DOI":"10.1016\/j.msard.2021.102947","article-title":"Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study","volume":"52","author":"Barzegar","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"B81","doi-asserted-by":"publisher","first-page":"103697","DOI":"10.1016\/j.msard.2022.103697","article-title":"Post COVID-19 infection neuromyelitis optica spectrum disorder (NMOSD): a case report-based systematic review","volume":"60","author":"Mirmosayyeb","year":"2022","journal-title":"Mult Scler Relat Disord."},{"key":"B82","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s13760-021-01691-5","article-title":"Demyelination as a result of an immune response in patients with COVID-19","volume":"121","author":"Shabani","year":"2021","journal-title":"Acta Naurol Belg."},{"key":"B83","doi-asserted-by":"publisher","first-page":"755333","DOI":"10.3389\/fimmu.2021.755333","article-title":"Multiple sclerosis and SARS-CoV-2: has the interplay started?","volume":"12","author":"Bellucci","year":"2021","journal-title":"Front Immunol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1018785\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T16:22:56Z","timestamp":1669911776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.1018785\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":83,"alternative-id":["10.3389\/fneur.2022.1018785"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.1018785","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,1]]},"article-number":"1018785"}}